RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.

PURPOSE: Phase II trial to compare the effectiveness of trastuzumab alone and in combination with docetaxel in treating patients who have metastatic prostate cancer that is refractory to hormone therapy.

OBJECTIVES:

• Compare the efficacy and toxicity of docetaxel (arm I) vs trastuzumab (Herceptin) (arm II), followed by a combination of docetaxel and trastuzumab in patients with androgen-independent or hormone-refractory metastatic, Her2/neu-positive prostate cancer. (Arm I closed to accrual effective 07/30/2001.)

OUTLINE: This is a multicenter study.

• Arm I: Patients receive docetaxel IV over 1 hour weekly for 6 weeks. Treatment continues every 8 weeks for at least 2 courses in the absence of unacceptable toxicity. (Arm I closed to accrual effective 07/30/2001. Arm I patients crossover to arm II.)
• Arm II: Patients receive trastuzumab (Herceptin) IV over 30-90 minutes weekly for 8 weeks. Treatment continues every 8 weeks for at least 2 courses in the absence of unacceptable toxicity.

Patients with progressive or stable disease after 2 courses of single-agent therapy receive docetaxel IV over 1 hour on day 1 of each week for 6 consecutive weeks and trastuzumab IV over 30-90 minutes on day 1 of each week for 8 consecutive weeks. Treatment continues every 8 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.

Patients with complete or partial response to single-agent therapy continue on that therapy until experiencing progressive or stable disease. The patients then proceed to combination therapy.

Patients are followed until death.

PROJECTED ACCRUAL: A total of 108-160 patients (54-80 per treatment arm) will be accrued for this study. (Arm I closed to accrual effective 07/30/2001.)

• Biological: trastuzumab
• Drug: docetaxel

DISEASE CHARACTERISTICS:

• Histologically confirmed stage IV prostate cancer (any T, any N, M1, any G; D3)
• Clinical evidence of metastatic disease in bone or soft tissue
• Her2/neu-positive (2+ and 3+) by immunochemistry or fluorescent in situ hybridization

• Androgen-independent

  • Serum PSA at least 10 ng/mL that has risen on 3 successive evaluations after prior hormonal therapy
  • At least 1 month since prior antiandrogen therapy (e.g., flutamide, bicalutamide, or nilutamide) and rising PSA levels with 1 of the 2 rising PSA levels, measured at least 2 weeks apart, after antiandrogen withdrawal
• Bone only disease and elevated PSA alone allowed
• LHRH analog therapy must continue in patients who have not had prior orchiectomy and have castrate levels of testosterone

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• SWOG 0-2

Life expectancy:

• At least 12 weeks

Hematopoietic:

• WBC at least 3,500/mm3
• Absolute granulocyte count at least 1,800/mm3
• Platelet count at least lower limit of normal (LLN)

Hepatic:

• Bilirubin no greater than 2 times upper limit of normal (ULN)
• SGOT no greater than 2 times ULN

Renal:

• Creatinine no greater than 1.6 mg/dL
• Creatinine clearance at least 50 mL/min

Cardiovascular:

• Ejection fraction more than 50% or more than LLN by MUGA scan or 2-D echocardiogram
• No symptomatic coronary artery disease
• No active ischemia on EKG

Other:

• Fertile patients must use effective contraception
• No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No concurrent biologic therapy

Chemotherapy:

• No more than one prior nonanthracycline chemotherapy regimen (including suramin)

Endocrine therapy:

• See Disease Characteristics
• No concurrent corticosteroids as antiemetic

Radiotherapy:

• At least 4 weeks since prior radiotherapy
• At least 3 months since prior strontium chloride Sr 89 and recovered
• No concurrent radiotherapy to measurable lesions

Surgery:

• See Disease Characteristics